NANTKWEST, INC. (NASDAQ:NK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

NANTKWEST, INC. (NASDAQ:NK) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On April16, 2018, John T. Potts, Jr., M.D. resigned from the board of directors of NantKwest, Inc. (the “Company”) effective immediately. Dr.Pott’s resignation was for personal reasons and not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.


About NANTKWEST, INC. (NASDAQ:NK)

NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, non-hodgkin lymphoma and myelodysplastic syndrome.

NANTKWEST, INC. (NASDAQ:NK) Recent Trading Information

NANTKWEST, INC. (NASDAQ:NK) closed its last trading session up +0.21 at 4.22 with shares trading hands.

An ad to help with our costs